Amicus Therapeutics, Inc.
FOLD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $4 | $4 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $3 | $4 | $4 | $3 |
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 32.3% | 21.3% | 7.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 90% | 90.7% | 88.3% | 88.7% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 5.6% | -23.1% | -60.6% | -66.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -10.6% | -38% | -71.9% | -82% |
| EPS Diluted | -0.18 | -0.51 | -0.82 | -0.92 |
| % Growth | 64.7% | 37.8% | 10.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |